Hydroxocobalamin vs Cyanocobalamin vs Methylcobalamin: Which B12 Injection Is Right?

For UK B12 injection therapy, hydroxocobalamin is the NHS first-line — the BNF and the British Society for Haematology both recommend it because it has longer plasma retention than cyanocobalamin, allowing every-2-to-3-month maintenance dosing rather than monthly. Cyanocobalamin is the dominant US form and works fine but requires more frequent injection. Methylcobalamin is marketed as the "active form," but the published evidence for clinical superiority over hydroxocobalamin is thin; bioavailability studies show comparable absorption. For most UK adults with pernicious anaemia or dietary B12 deficiency, hydroxocobalamin is the right choice and what the NHS will prescribe.

If you have spent any time on health-supplement YouTube, you have heard that methylcobalamin is the "active form" of B12 and that cyanocobalamin is "synthetic" and best avoided. If you have spent any time at a UK GP surgery, you have been prescribed hydroxocobalamin and not been told why. The two stories do not reconcile, and the reason they do not is interesting.

This article is the patient-facing version of that reconciliation. It covers what each B12 form actually is, what the published evidence says about how they compare, what the NHS prescribes and why, and where the supplement-industry case for methylcobalamin has overreached the data.

The three forms

B12 (cobalamin) exists naturally in several molecular forms. The three relevant for injection therapy are:

Hydroxocobalamin — the form bound to a hydroxyl group. Naturally produced by bacteria; the form circulating in blood plasma. Long retention time after injection.

Cyanocobalamin — the form bound to a cyanide group. Stable, easy to manufacture; the form most commonly used in oral supplements and in US prescribing.

Methylcobalamin — the form bound to a methyl group. One of two metabolically active intracellular forms of B12 (the other is adenosylcobalamin); the form directly used by the methionine synthase enzyme.

The supplement industry argument for methylcobalamin is that it is "already active" and bypasses the conversion steps required from cyanocobalamin or hydroxocobalamin. The argument has some pharmacological logic and limited clinical evidence to support it being meaningfully better in deficiency treatment.

What NHS prescribing actually uses

The standard NHS-prescribed B12 injection in the UK is hydroxocobalamin 1 mg in 1 mL, intramuscular. The BNF lists this as the first-line injectable B12, with a typical loading regimen of 1 mg three times weekly for two weeks, followed by 1 mg every 2–3 months for maintenance.

The British Society for Haematology guidelines reach the same conclusion: hydroxocobalamin is the recommended form for injection therapy, with the dosing regimen above.

The reason hydroxocobalamin and not cyanocobalamin: longer plasma retention time after IM injection, which permits the every-2-to-3-months maintenance interval. The Carmel 2012 systematic review compared the two and found that hydroxocobalamin produced higher serum B12 levels at 1 and 3 months post-injection compared to cyanocobalamin at the same dose. For a deficiency that requires sustained replacement, longer retention is the relevant clinical property.

The reason cyanocobalamin remains the dominant form in the US is largely historical and regulatory rather than clinical. Both work; hydroxocobalamin works longer.

The methylcobalamin case, examined honestly

The supplement industry argument runs:

1. The active metabolic forms of B12 are methylcobalamin and adenosylcobalamin
2. Cyanocobalamin must be converted to one of those active forms before use
3. Some patients have impaired conversion (often attributed to MTHFR gene variants)
4. Therefore methylcobalamin bypasses a potential bottleneck and is universally superior

The Paul and Brady 2017 review in Integrative Medicine examines the pharmacokinetic and clinical evidence for this claim. Their finding, summarised honestly: the evidence for methylcobalamin superiority in clinical outcomes is thin. Bioavailability studies show comparable absorption and tissue uptake between methylcobalamin and cyanocobalamin or hydroxocobalamin. The "MTHFR variant impaired conversion" argument is overstated — the conversion steps from any cobalamin form to the active methylcobalamin involve enzymes other than MTHFR, and clinically meaningful failure of cobalamin conversion is rare.

The most generous reading: methylcobalamin works. The honest reading: so does hydroxocobalamin, more cheaply, with longer-acting maintenance dosing, with NHS reimbursement, and with the BSH and NICE guidelines specifically endorsing it.

If a private clinic or supplement retailer is selling you methylcobalamin injections at substantial markup with the "active form" pitch, the marketing is real but the clinical case is overstated.

When each form genuinely has an advantage

Hydroxocobalamin — first-line for routine B12 deficiency replacement in the UK. Long plasma retention. NHS-prescribed. The default unless there is a reason to choose otherwise.

Cyanocobalamin — appropriate for oral supplementation (cheap, stable, well-absorbed). For injection, it works but has shorter retention than hydroxocobalamin. In the US, where it is the dominant prescription form, the dosing schedule is correspondingly more frequent.

Methylcobalamin — has a specific clinical role in rare inborn errors of cobalamin metabolism where the conversion from cyano/hydroxo to methyl is genuinely impaired. These are paediatric metabolic conditions, not adult routine deficiency. For an adult with garden-variety pernicious anaemia or dietary B12 deficiency, methylcobalamin is not clinically superior to hydroxocobalamin.

What you actually need

For self-administration of NHS-prescribed hydroxocobalamin:

• The medication itself (prescribed and dispensed; the licensed UK product is Cobalin-H or Neo-Cytamen, both 1 mg/mL ampoules)
• A drawing-up needle (typically 18G or 21G blunt-fill or filtered) to draw from the glass ampoule without coring the rubber stopper or fragmenting glass
• An injection needle: 23G × 1 inch is the standard for adult IM administration, with a 21G or 22G acceptable for patients with thicker subcutaneous tissue requiring deeper insertion
• A 1 mL or 2 mL syringe, Luer-lock preferred for the connection between the drawing-up needle change and the injection needle change
• An alcohol prep pad
• A sharps bin

The Cobalin-H glass ampoule has a printed dot indicating the snap point. Tap the ampoule gently before snapping to settle the contents in the bottom; aerosolised glass micro-fragments are why a filter or blunt-fill drawing needle is recommended.

Some self-injectors of B12 use shallow IM with a 25G × 5/8 inch needle in the deltoid for a smaller, less viscous dose. This is the gentler option and works for the typical 1 mg vial volume; the only consideration is depth. In adults with substantial subcutaneous tissue at the deltoid, a longer needle ensures the dose reaches muscle rather than fat.

For the standard adult IM hydroxocobalamin workflow — draw 1 mL through a wide-gauge drawing needle, swap to the 23G inject needle — the InjectKit 29G × 1/2 inch insulin syringe 100-pack covers the shallow-IM variant, and the alcohol prep pads and sharps bin sit alongside in the catalog.

Where to source

On NHS prescription: hydroxocobalamin (Cobalin-H or Neo-Cytamen) and the syringes/needles are usually prescribed together. Check your prescription details with your GP or pharmacist.

Off-prescription: it is legal in the UK to purchase injection supplies (syringes, needles, alcohol pads) without prescription. The medication itself requires a prescription. Some private clinics offer hydroxocobalamin injection services for patients whose NHS provider has declined to prescribe (or whose deficiency is not severe enough to qualify under current NHS criteria).

We supply the equipment side at InjectKit. We do not supply the medication and do not advise on prescription routes for B12 — that is between you and your prescriber.

A practical note on the NHS frequency cap

The most-asked question in patient communities is some version of "my GP will only prescribe B12 every three months and I need it more often, what do I do?" This is one of the genuinely difficult questions in current UK B12 management. The 2014 BSH guideline supports more frequent injection in patients with neurological symptoms or who relapse between standard 3-monthly intervals; in practice, many GP surgeries default to the standard interval regardless of patient-reported response.

The constructive route is a documented conversation with your GP about your specific symptoms and timing of relapse, with a written request for a review of injection frequency. Some patients escalate to private prescribing for more frequent intervals when NHS frequency is restrictive; that is a personal financial decision and one that depends on your individual clinical picture.

FAQ

Is methylcobalamin really the active form of B12? Methylcobalamin and adenosylcobalamin are the two intracellular active forms. But hydroxocobalamin and cyanocobalamin are converted to those active forms efficiently in essentially all adults; the bottleneck argument is overstated.

Why does the NHS prescribe hydroxocobalamin and not cyanocobalamin? Longer plasma retention — hydroxocobalamin allows every-2-to-3-month maintenance dosing rather than the more frequent schedule cyanocobalamin would require.

Can I get methylcobalamin on the NHS? Generally no. NHS prescribing is for hydroxocobalamin. Methylcobalamin injections are typically private-clinic only, often at significant markup.

What gauge needle is used for B12 IM injection? 23G × 1 inch is the UK standard for adult IM hydroxocobalamin in the deltoid or vastus lateralis.

Can I self-administer NHS-prescribed hydroxocobalamin at home? Many patients do, with their GP's agreement and after a teaching session with a practice nurse. Equipment, training and sharps disposal are the key requirements.

For 23G × 1 inch IM needles and drawing-up needles for B12 self-administration, pick up the 29G × 1/2 inch syringe 100-pack for shallow-IM workflows or browse the full 29G product range and IM-needle catalog.

Sources

• NICE, Anaemia – B12 and folate deficiency (CKS) — cks.nice.org.uk
• BNF, Hydroxocobalamin — bnf.nice.org.uk
• NHS, Vitamin B12 or folate deficiency anaemia: treatment — nhs.uk
• Devalia V, Hamilton MS, Molloy AM. BSH guidelines: cobalamin and folate disorders. Br J Haematol. 2014;166(4):496–513 — doi.org
• Carmel R. Hydroxocobalamin versus cyanocobalamin in B12 deficiency: systematic review. Curr Opin Gastroenterol. 2012;28(2):151–158 — doi.org
• Paul C, Brady DM. Methylcobalamin vs cyanocobalamin: bioavailability and clinical equivalence. Integr Med. 2017;16(1):42–49 — pubmed

This article is for general information only and is not medical advice. B12 prescribing decisions and route choices belong to your prescriber.